Neuroscience News and Research

RSS

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

AstraZeneca and the University of Virginia (UVa) in Charlottesville, today announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

15 Dec 2009

RORalpha protein revealed as an essential regulator of inflammatory factors

How do the brain cells called astrocytes ensure the protection of neurons? By studying the protagonists in the protection and satisfactory functioning of neurons, scientists at the Laboratoire Neurobiologie des Processus Adaptatifs (CNRS/UPMC) have found a mechanism that clarifies the role of astrocytes.

15 Dec 2009

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease.

15 Dec 2009

Nanoparticle could allow diagnosis and treatment in one visit

Researchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent dye and kills them with heat.

15 Dec 2009

USPTO issues Notice of Allowance to Transcept Pharmaceuticals for Intermezzo claims

Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.

15 Dec 2009

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Teva Pharmaceutical Industries, Ltd. today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions.

15 Dec 2009

Postmenopausal women who take antidepressants face increased risk for stroke and death

Postmenopausal women who take antidepressants face a small but statistically significant increased risk for stroke and death compared with those who do not take the drugs. The new findings are from the federally-funded, multi-institution, Women's Health Initiative Study sponsored by the National Institutes of Health, and the results are published in the December 14 online edition of Archives of Internal Medicine.

14 Dec 2009

Psychopharmacology expert calls for more mental health staffing at army bases

The recent shootings at the Ft. Hood, Texas army base, allegedly by an army psychiatrist, have placed much-needed focus on mental health care in the army. In an article published in the December issue of the journal CNS Spectrum, renowned psychopharmacology expert Stephen M. Stahl, MD, PhD, calls for increased mental health staffing at Fort Hood and other army bases.

14 Dec 2009

New biosensors show how schizophrenia drugs alter brain chemistry

Scientists have resolved a question about how a popular class of drugs used to treat schizophrenia works using biosensors that reveal previously hidden components of chemical communication in the brain.

14 Dec 2009

Oconomowoc Memorial Hospital performs partial knee resurfacing surgery using MAKOplasty technology

For the first time in Wisconsin, patients suffering from arthritis pain have access to a new procedure that uses the precision of robotics to perform partial knee resurfacing surgery. The technology, called MAKOplasty®, is a minimally invasive surgical option that results in shorter hospital stays and faster healing than traditional knee surgeries.

11 Dec 2009

Scientists explore new potential therapies for Parkinson's disease

Following up on their previous work showing the rescue of dopamine neurons by chemicals that interact with the retinoid X receptor (RXR), researchers have now investigated the potential of these chemicals, known as RXR ligands, for the treatment of Parkinson's disease.

11 Dec 2009

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%

11 Dec 2009

Mouse study shows delaying the ageing process may offer protection against Alzheimer’s disease

Aging is the single greatest risk factor for Alzheimer's disease. In their latest study, researchers at the Salk Institute for Biological Studies found that simply slowing the aging process in mice prone to develop Alzheimer's disease prevented their brains from turning into a neuronal wasteland.

10 Dec 2009

New brain metastases treatment guidelines

New treatment guidelines for patients with brain metastases are now available from the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS).

10 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

Decade of the Mind: A multidisciplinary effort to understand the phenomenon of mind

As we seek a better understanding of the workings of the human mind, we are continually confronted by fresh ethical, legal, and social questions. Now, researchers are increasingly emphasizing the role of a new discipline, neuroethics, to guide the search for answers to those questions.

10 Dec 2009

Cell transplants may yield new therapies for dementia patients

Nerve cells transplanted into brain-damaged rats helped them to fully recover their ability to learn and remember, probably by promoting nurturing, protective growth factors, according to a new study.

10 Dec 2009

NYSE Amex to delist Cortex Pharmaceuticals

Cortex Pharmaceuticals, Inc. announced that it has received notification from the NYSE Amex LLC indicating that, due to the Company’s non-compliance with certain continued listing standards as previously reported, the Exchange intends to delist the Company’s common stock from the NYSE Amex effective as of the close of business on Friday, December 11, 2009.

9 Dec 2009

Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences

Knopp Neurosciences Inc. (“Knopp”) announced the presentation today of encouraging clinical results in a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis (“ALS”).

9 Dec 2009

No co-pays for patients enrolled in AstraZeneca's Medicare Part D prescription savings program

AstraZeneca announced today that patients enrolled in the company's Medicare Part D prescription savings program will no longer pay co-pays for their medicines through the program.

9 Dec 2009

Neuroscience News and Research

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

RORalpha protein revealed as an essential regulator of inflammatory factors

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Nanoparticle could allow diagnosis and treatment in one visit

USPTO issues Notice of Allowance to Transcept Pharmaceuticals for Intermezzo claims

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Postmenopausal women who take antidepressants face increased risk for stroke and death

Psychopharmacology expert calls for more mental health staffing at army bases

New biosensors show how schizophrenia drugs alter brain chemistry

Oconomowoc Memorial Hospital performs partial knee resurfacing surgery using MAKOplasty technology

Scientists explore new potential therapies for Parkinson's disease

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

Mouse study shows delaying the ageing process may offer protection against Alzheimer’s disease

New brain metastases treatment guidelines

Eli Lilly provides financial guidance for 2010

Decade of the Mind: A multidisciplinary effort to understand the phenomenon of mind

Cell transplants may yield new therapies for dementia patients

NYSE Amex to delist Cortex Pharmaceuticals

Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences

No co-pays for patients enrolled in AstraZeneca's Medicare Part D prescription savings program

Neuroscience - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News